| ￥2300 | |
| Z06019-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 38.4 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of B2M/beta 2-Microglobulin hFc Chimera, Mouse is greater than 95% as determined by SEC-HPLC. »
B2M/beta 2-Microglobulin hFc Chimera, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The genetic and functional analysis of β2-microglobulin (B2M), a component of the HLA class-I complex.Acquired homozygous loss of B2M that caused lack of cell-surface HLA Class I expression in the tumor and a matched patient-derived xenograft (PDX). Downregulation of B2M was also found in two additional PDXs established from ICI-resistant tumors. |
| Synonyms | Beta-2-microglobulin;B2M;β-2-microglobulin |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
